- Home
- ESLA vs NSPR Comparison
ESLA vs NSPR Comparison
Compare ESLA & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | NSPR |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.5M | 72.1M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | ESLA | NSPR |
|---|---|---|
| Price | $1.12 | $1.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $8.00 | $4.00 |
| AVG Volume (30 Days) | 28.4K | ★ 212.4K |
| Earning Date | 05-26-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.78 | $1.02 |
| 52 Week High | $3.15 | $2.93 |
Technical Indicators
Market Signals| Indicator | ESLA | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 33.78 | 28.99 |
| Support Level | $0.99 | N/A |
| Resistance Level | $1.35 | $1.29 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 4.11 | 5.18 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
About NSPR InspireMD Inc.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.